Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ischemic Heart Disease

  Free Subscription

Articles published in
JAMA
    September 2017
  1. DEVEREAUX PJ, Biccard BM, Chan MTV
    High-Sensitivity Troponin Levels, Ischemia, and Mortality-Reply.
    JAMA. 2017;318:865.
    >> Share

  2. SMILOWITZ NR
    High-Sensitivity Troponin Levels, Ischemia, and Mortality.
    JAMA. 2017;318:864-865.
    >> Share

    August 2017
  3. FERENCE BA, Kastelein JJP, Ginsberg HN, Chapman MJ, et al
    Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk.
    JAMA. 2017 Aug 28. doi: 10.1001/jama.2017.11467.
    >> Share

  4. FELKER GM, Anstrom KJ, Adams KF, Ezekowitz JA, et al
    Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
    JAMA. 2017;318:713-720.
    >> Share

  5. CHOLLEY B, Caruba T, Grosjean S, Amour J, et al
    Effect of Levosimendan on Low Cardiac Output Syndrome in Patients With Low Ejection Fraction Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass: The LICORN Randomized Clinical Trial.
    JAMA. 2017;318:548-556.
    >> Share

  6. KRUMHOLZ HM
    Treatment of Cholesterol in 2017.
    JAMA. 2017;318:417-418.
    >> Share

    July 2017
  7. LARSSON SC, Burgess S, Michaelsson K
    Association of Genetic Variants Related to Serum Calcium Levels With Coronary Artery Disease and Myocardial Infarction.
    JAMA. 2017;318:371-380.
    >> Share

  8. IOANNIDIS JPA
    Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
    JAMA. 2017 Jul 24. doi: 10.1001/jama.2017.6765.
    >> Share

  9. DHARMARAJAN K, Wang Y, Lin Z, Normand ST, et al
    Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge.
    JAMA. 2017;318:270-278.
    >> Share

  10. GROSSMAN DC, Bibbins-Domingo K, Curry SJ, Barry MJ, et al
    Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2017;318:167-174.
    >> Share

  11. PATNODE CD, Evans CV, Senger CA, Redmond N, et al
    Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Known Cardiovascular Disease Risk Factors: Updated Evidence Report and Systematic Review for the US Preventive Services Tas
    JAMA. 2017;318:175-193.
    >> Share

  12. JIN J
    Counseling on Healthy Living to Prevent Cardiovascular Disease in Adults Without Risk Factors.
    JAMA. 2017;318:210.
    >> Share

  13. YU J, Zhou Z, McEvoy RD, Anderson CS, et al
    Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis.
    JAMA. 2017;318:156-166.
    >> Share

  14. GOTTLIEB DJ
    Does Obstructive Sleep Apnea Treatment Reduce Cardiovascular Risk?: It Is Far Too Soon to Say.
    JAMA. 2017;318:128-130.
    >> Share

  15. GREENLAND P, Fuster V
    Cardiovascular Risk Factor Control for All.
    JAMA. 2017;318:130-131.
    >> Share

    June 2017
  16. BUDOFF MJ, Ellenberg SS, Snyder PJ
    Changes in Coronary Artery Plaque With Testosterone Therapy-Reply.
    JAMA. 2017;317:2451.
    >> Share

  17. DHINDSA S, Wilson MF, Dandona P
    Changes in Coronary Artery Plaque With Testosterone Therapy.
    JAMA. 2017;317:2450.
    >> Share

  18. NAVATHE AS, Song Z, Emanuel EJ
    The Next Generation of Episode-Based Payments.
    JAMA. 2017;317:2371-2372.
    >> Share

  19. CHILDERS CP, Maggard-Gibbons M, Shekelle PG
    Antiplatelet Therapy in Patients With Coronary Stents Undergoing Elective Noncardiac Surgery: Continue, Stop, or Something in Between?
    JAMA. 2017 Jun 19. doi: 10.1001/jama.2017.7845.
    >> Share

    May 2017
  20. SLOMSKI A
    Redefining Acute Coronary Syndrome Therapy.
    JAMA. 2017;317:2054.
    >> Share

  21. ROTH GA, Dwyer-Lindgren L, Bertozzi-Villa A, Stubbs RW, et al
    Trends and Patterns of Geographic Variation in Cardiovascular Mortality Among US Counties, 1980-2014.
    JAMA. 2017;317:1976-1992.
    >> Share

  22. MENSAH GA, Goff DC, Gibbons GH
    Cardiovascular Mortality Differences-Place Matters.
    JAMA. 2017;317:1955-1957.
    >> Share

    April 2017
  23. NICHOLLS SJ, Somaratne R, Nissen SE
    Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis-Reply.
    JAMA. 2017;317:1691.
    >> Share

  24. ALKHALIL M, Choudhury RP
    Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis.
    JAMA. 2017;317:1690-1691.
    >> Share

  25. MURRAY SW
    Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis.
    JAMA. 2017;317:1690.
    >> Share

  26. DEVEREAUX PJ, Biccard BM, Sigamani A, Xavier D, et al
    Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery.
    JAMA. 2017;317:1642-1651.
    >> Share

  27. SCHWARTZ MLB, Williams MS, Murray MF
    Adding Protective Genetic Variants to Clinical Reporting of Genomic Screening Results: Restoring Balance.
    JAMA. 2017;317:1527-1528.
    >> Share

    March 2017
  28. KHERA AV, Won HH, Peloso GM, O'Dushlaine C, et al
    Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease.
    JAMA. 2017;317:937-946.
    >> Share

    February 2017
  29. BUDOFF MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, et al
    Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone.
    JAMA. 2017;317:708-716.
    >> Share

  30. AGORITSAS T, Merglen A, Shah ND, O'Donnell M, et al
    Adjusted Analyses in Studies Addressing Therapy and Harm: Users' Guides to the Medical Literature.
    JAMA. 2017;317:748-759.
    >> Share

  31. BILECEN S, de Groot JA, Kalkman CJ, Spanjersberg AJ, et al
    Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial.
    JAMA. 2017;317:738-747.
    >> Share

  32. EMDIN CA, Khera AV, Natarajan P, Klarin D, et al
    Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease.
    JAMA. 2017;317:626-634.
    >> Share

    January 2017
  33. SILVERMAN MG, Im K, Sabatine MS
    Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk-Reply.
    JAMA. 2017;317:440.
    >> Share

  34. ZAFAR K, Inayat M
    Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk.
    JAMA. 2017;317:439-440.
    >> Share

  35. NAVARESE EP, Kolodziejczak M, De Servi S
    Interventions to Lower Low-Density Lipoprotein Cholesterol and Cardiovascular Risk.
    JAMA. 2017;317:439.
    >> Share

  36. BRAGG F, Holmes MV, Iona A, Guo Y, et al
    Association Between Diabetes and Cause-Specific Mortality in Rural and Urban Areas of China.
    JAMA. 2017;317:280-289.
    >> Share

  37. GREENWOOD JP, Brown JM, Berry C
    Alternatives in the Evaluation of Suspected Coronary Heart Disease-Reply.
    JAMA. 2017;317:212-213.
    >> Share

  38. SCHWITTER J
    Alternatives in the Evaluation of Suspected Coronary Heart Disease.
    JAMA. 2017;317:211-212.
    >> Share

  39. BITTENCOURT MS, Fernandes JL
    Alternatives in the Evaluation of Suspected Coronary Heart Disease.
    JAMA. 2017;317:211.
    >> Share

  40. FOROUZANFAR MH, Liu P, Roth GA, Ng M, et al
    Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015.
    JAMA. 2017;317:165-182.
    >> Share

    December 2016
  41. SLOMSKI A
    Celecoxib Similar to 2 NSAIDs for Cardiovascular Safety.
    JAMA. 2016;316:2589.
    >> Share

  42. DESAI NR, Ross JS, Kwon JY, Herrin J, et al
    Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions.
    JAMA. 2016;316:2647-2656.
    >> Share

  43. MORA S, Manson JE
    Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease-Reply.
    JAMA. 2016;316:2276-2277.
    >> Share

  44. STOVITZ SD, Satin DJ, Shrier I
    Shared Decision Making Regarding Aspirin in Primary Prevention of Cardiovascular Disease.
    JAMA. 2016;316:2276.
    >> Share

    November 2016
  45. NICHOLLS SJ, Puri R, Anderson T, Ballantyne CM, et al
    Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    JAMA. 2016 Nov 15. doi: 10.1001/jama.2016.16951.
    >> Share

  46. NAVAR AM, Peterson ED, Wojdyla D, Sanchez RJ, et al
    Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence.
    JAMA. 2016;316:2041-2043.
    >> Share

  47. KAVOUSI M, Desai CS, Ayers C, Blumenthal RS, et al
    Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women: A Meta-analysis.
    JAMA. 2016 Nov 15. doi: 10.1001/jama.2016.17020.
    >> Share

  48. RODRIGUEZ F, Harrington RA
    Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering.
    JAMA. 2016;316:1967-1968.
    >> Share

  49. BIBBINS-DOMINGO K, Grossman DC, Curry SJ, Davidson KW, et al
    Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.
    JAMA. 2016;316:1997-2007.
    >> Share

  50. CHOU R, Dana T, Blazina I, Daeges M, et al
    Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2016;316:2008-2024.
    >> Share

  51. SONG Z, Blumenthal DM
    Expanding Payment Reform in Medicare: The Cardiology Episode-Based Payment Model.
    JAMA. 2016;316:1973-1974.
    >> Share

  52. ABBASI J
    Do Apollo Astronaut Deaths Shine a Light on Deep Space Radiation and Cardiovascular Disease?
    JAMA. 2016 Nov 9. doi: 10.1001/jama.2016.12601.
    >> Share

  53. LEGATO MJ, Johnson PA, Manson JE
    Consideration of Sex Differences in Medicine to Improve Health Care and Patient Outcomes.
    JAMA. 2016;316:1865-1866.
    >> Share

    October 2016
  54. HAMPTON T
    Reservoir of Genetic Data Related to Cardiovascular Disease.
    JAMA. 2016;316:1349.
    >> Share

  55. LOTTA LA, Sharp SJ, Burgess S, Perry JR, et al
    Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
    JAMA. 2016;316:1383-1391.
    >> Share

    September 2016
  56. SILVERMAN MG, Ference BA, Im K, Wiviott SD, et al
    Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
    JAMA. 2016;316:1289-97.
    >> Share

  57. MILLS K, He J
    Sodium Excretion, Cardiovascular Disease, and Chronic Kidney Disease.
    JAMA. 2016;316:1112-3.
    >> Share

  58. ALMIRALL J
    Sodium Excretion, Cardiovascular Disease, and Chronic Kidney Disease.
    JAMA. 2016;316:1112.
    >> Share

  59. HURSITOGLU M
    Sodium Excretion, Cardiovascular Disease, and Chronic Kidney Disease.
    JAMA. 2016;316:1112.
    >> Share

  60. HEMKENS LG, Ewald H, Briel M
    Colchicine and Prevention of Cardiovascular Events.
    JAMA. 2016;316:1106-7.
    >> Share

    August 2016
  61. HALL M, Dondo TB, Yan AT, Goodman SG, et al
    Association of Clinical Factors and Therapeutic Strategies With Improvements in Survival Following Non-ST-Elevation Myocardial Infarction, 2003-2013.
    JAMA. 2016 Aug 30. doi: 10.1001/jama.2016.10766.
    >> Share

  62. BOHULA EA, Antman EM
    Management of Non-ST-Elevation Myocardial Infarction: The Bright Gleam of Progress, But Much Work Remains.
    JAMA. 2016 Aug 30. doi: 10.1001/jama.2016.11940.
    >> Share

  63. GREENWOOD JP, Ripley DP, Berry C, McCann GP, et al
    Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates: The CE-MARC 2 Randomized Clinical Trial.
    JAMA. 2016 Aug 29. doi: 10.1001/jama.2016.12680.
    >> Share

  64. KAZI DS, Moran AE, Coxson PG, Penko J, et al
    Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    JAMA. 2016;316:743-53.
    >> Share

  65. LIVINGSTON EH
    JAMA PATIENT PAGE. Screening for Lipid Disorders in Children and Adolescents.
    JAMA. 2016;316:678.
    >> Share

  66. LOZANO P, Henrikson NB, Dunn J, Morrison CC, et al
    Lipid Screening in Childhood and Adolescence for Detection of Familial Hypercholesterolemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2016;316:645-55.
    >> Share

  67. LOZANO P, Henrikson NB, Morrison CC, Dunn J, et al
    Lipid Screening in Childhood and Adolescence for Detection of Multifactorial Dyslipidemia: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA. 2016;316:634-44.
    >> Share

    July 2016
  68. NUTI SV, Qin L, Krumholz HM
    Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals--Reply.
    JAMA. 2016;316:346.
    >> Share

  69. RADOMSKI TR, Fine MJ, Gellad WF
    Outcome After Admission at Veterans Affairs vs Non-Veterans Affairs Hospitals.
    JAMA. 2016;316:345-6.
    >> Share

    June 2016
  70. CHOBANIAN AV
    SPRINT Results in Older Patients: How Low to Go?
    JAMA. 2016;315:2669-70.
    >> Share

  71. GANZ P, Heidecker B, Hveem K, Jonasson C, et al
    Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease.
    JAMA. 2016;315:2532-41.
    >> Share

  72. SABATINE MS
    Using Aptamer-Based Technology to Probe the Plasma Proteome for Cardiovascular Disease Prediction.
    JAMA. 2016;315:2525-6.
    >> Share

  73. MORA S, Ames JM, Manson JE
    Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease: Shared Decision Making in Clinical Practice.
    JAMA. 2016 Jun 20. doi: 10.1001/jama.2016.8362.
    >> Share

  74. HONG SJ, Kim BK, Hong MK
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation--Reply.
    JAMA. 2016;315:2469-70.
    >> Share

  75. STEINVIL A, Waksman R, Garcia-Garcia HM
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation.
    JAMA. 2016;315:2469.
    >> Share

  76. TUNCEZ A, Altunkeser BB
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation.
    JAMA. 2016;315:2468-9.
    >> Share

  77. HOFFER EK
    Ultrasound vs Angiography for Drug-Eluting Stent Implantation.
    JAMA. 2016;315:2468.
    >> Share

  78. MANSON JE, Shufelt CL, Robins JM
    The Potential for Postrandomization Confounding in Randomized Clinical Trials.
    JAMA. 2016;315:2273-4.
    >> Share

    May 2016
  79. MILLS KT, Chen J, Yang W, Appel LJ, et al
    Sodium Excretion and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease.
    JAMA. 2016;315:2200-10.
    >> Share

  80. POWE NR, Bibbins-Domingo K
    Dietary Salt, Kidney Disease, and Cardiovascular Health.
    JAMA. 2016;315:2173-4.
    >> Share

  81. WILLIAMSON JD, Supiano MA, Applegate WB, Berlowitz DR, et al
    Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >/=75 Years: A Randomized Clinical Trial.
    JAMA. 2016 May 19. doi: 10.1001/jama.2016.7050.
    >> Share

    April 2016
  82. PENCINA MJ, Peterson ED
    Moving From Clinical Trials to Precision Medicine: The Role for Predictive Modeling.
    JAMA. 2016;315:1713-4.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016